HUTCHMED (China) Limited
HUTCHMED (China) Limited (HKSE: 13) is trading at HK$23.10, about ₹283 at today's HKD/INR rate, as of 30 Sep 2026, 3:29 AM ET, up 3.59% today. Indian residents can buy HUTCHMED (China) from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$21.96
Today's high
HK$23.56
52 week low
HK$15.57
52 week high
HK$26.00
13 opened at HK$22.22, closed previously at HK$22.30, and has traded between HK$15.57 and HK$26.00 over the past 52 weeks.
About
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Fruquintinib targets CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a broad spectrum of gastrointestinal and solid tumors. Another prominent compound, Surufatinib, is indicated for various neuroendocrine tumors (NETs) including pancreatic and non-pancreatic types, alongside biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and other solid tumors. Further pipeline assets feature HMPL-523, a spleen tyrosine kinase (Syk) inhibitor for treating hematological cancers and certain chronic immune diseases; HMPL-689, an inhibitor specifically targeting the PI3Kd isoform; and Tazemetostat, an EZH2 inhibitor utilized in the treatment of specific epithelioid sarcoma and follicular lymphoma patients. The company's development efforts also encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase (BTK) inhibitor; HMPL-453, aimed at intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; HMPL-653, developed for metastatic solid tumors and tenosynovial giant cell tumors; and the inhibitors Epitinib (HMPL-813) and Theliatinib (HMPL-309). HUTCHMED has forged strategic collaboration agreements with a number of significant pharmaceutical entities, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company, originally known as Hutchison China MediTech Limited, officially changed its name to HUTCHMED (China) Limited in May 2021.
Key statistics
Avg. volume
4.82M
Market cap
HK$20.08B
P/E Ratio
159.15
Price-to-sales ratio
4.66
Enterprise value
$2.34B
Free cash flow yield
-3.41%
Debt-to-equity ratio
0.07
Return on equity
36.91%
ROIC
-2.35%
Beta
0.43
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
$548.51M
Earnings per share
$0.52
Free cash flow
-$78.92M
Net profit margin
3.26%
Gross margin
0.20%
EBITDA
-$25.85M
Revenue growth
-12.96%
Similar securities
This is not an investment recommendation
How to buy HUTCHMED (China) from India
Indian residents can buy HUTCHMED (China) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for HUTCHMED (China) and place an order
Find HUTCHMED (China) by name or by its ticker, 13, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. HUTCHMED (China) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your HUTCHMED (China) position in HKD and INR. HUTCHMED (China) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in HUTCHMED (China) from India
Trading and taxes when buying HUTCHMED (China) from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneHUTCHMED (China) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Estate or inheritance tax
- May applyHong Kong has no estate duty.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy HUTCHMED (China) stock?
Yes. HUTCHMED (China) (13) has been listed on the Hong Kong Stock Exchange since 2021, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one HUTCHMED (China) share cost in rupees?
One HUTCHMED (China) share is HK$23.10 — about ₹283 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the HUTCHMED (China) price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying HUTCHMED (China) from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of HUTCHMED (China)?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on HUTCHMED (China) shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the HUTCHMED (China) price. Paasa issues a capital-gains statement for your return.
Does HUTCHMED (China) pay a dividend?
No. HUTCHMED (China) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade HUTCHMED (China) from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on HUTCHMED (China) shares held from India?
Hong Kong has no estate duty.
Do I have to declare HUTCHMED (China) shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your HUTCHMED (China) holding, its cost and its closing value.
How do I sell HUTCHMED (China) and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.